Monopar Therapeutics MNPR 深 滬
等待開盤 04-02 09:30:00 美东时间
55.39
+0.600
+1.10%
華盛通- 最 高58.22
- 今 開54.69
- 成交量 12.07万股
- 最 低 53.2414
- 昨 收 54.79
- 總市值 3.71亿
- 52周最高 105.00
- 市盈率 靜 --
- 換手率 1.80%
- 52周最低 28.40
- 委 比 -38.21%
- 總股本 669.21万
- 歷史最高 240.00
- 量 比 0.71
- 振 幅 9.09%
- 歷史最低 1.3695
- 每 手 1
- 風險率 19.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16
Monopar Therapeutics press release (MNPR): Q4 GAAP EPS of -$0.61 misses by $0.16. Cash, cash equivalents and short-term investments as of December 31, 2025, were $140.4 million. More on Monopar Therap...
03-28 04:47
Monopar Therapeutics Q4 EPS $(0.61) Misses $(0.54) Estimate
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 72.65 percent increase over losses of $(2.23) per share
03-28 01:06
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Monopar Therapeutics reported positive developments in 2025, including progress on ALXN1840 for Wilson disease, with plans to submit an NDA in mid-2026. The company strengthens leadership with Susan Rodriguez as Chief Commercial and Strategy Officer. 2025 financial results show a reduced net loss, with $140.4 million in cash reserves supporting operations through 2027. ALXN1840 demonstrated favorable safety and efficacy in multiple studies, and M...
03-27 17:00
Monopar Therapeutics Appoints Susan Rodriguez as Chief Commercial and Strategy Officer
Monopar Therapeutics Appoints Susan Rodriguez as Chief Commercial and Strategy Officer Monopar Therapeutics Inc. appointed Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In the newly created role, Rodriguez will lead the company’s commercial strategy and build-out a
03-02 21:01
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Monopar Therapeutics Inc. has appointed Susan Rodriguez as Chief Commercial and Strategy Officer. In this role, she will lead the company's commercial strategy and infrastructure development as it prepares to submit an NDA for ALXN1840, its investigational therapy for Wilson disease. With over 30 years of experience in biopharmaceutical leadership, Rodriguez brings a proven track record of successfully launching rare disease therapies and scaling...
03-02 13:00
美股大行评级 | 大摩将康宁目标价从103美元升至127美元；潜在涨幅1779.7%！IGC Pharma获Ascendiant Capital升目标价至5美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从4.75美元升至5美元；Brookline Capital：维持C4 Therapeutics"买入"评级，目标价从20美元升至30美元
02-24 10:27
BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target
BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.
02-23 20:55
美股大行评级 | 英特尔、美光科技、SanDisk等获大行上调目标价；纽约梅隆银行获5家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Rezolve AI"买入"评级，目标价从10美元升至12美元；HC Wainwright & Co.：维持Largo"买入"评级，目标价从2.9美元升至3.1美元
01-15 16:10
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Morgan Stanley Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $115
Morgan Stanley analyst Maxwell Skor initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $115.
01-09 21:02
